Opinion|Videos|January 31, 2025
Adverse Events of the Port Delivery System and Addressing Challenges With Adoption
Panelists discuss how careful patient selection and management of potential complications - including surgical risks, device-related adverse events, and cost-benefit considerations requiring operating room resources - are crucial factors in successfully implementing the port delivery system in clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the major adverse effects associated with the PDS, and which patients are not suitable candidates for this delivery system?
- What are some potential challenges to the adoption of the PDS, and how can retina specialists and surgeons address these to facilitate its integration into clinical practice?
- Need to go to the operating room- balancing cost versus benefits
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape
Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves ranibizumab biosimilar Lucamzi for wet AMD
2
Practical ways to extend anti-VEGF control in RVO, AMD, and DME
3
AAO 2026 recap: Christopher J. Rapuano, MD, on the meeting's themes
4
Comments from the FDA Advisory Committee meeting on SYD-101
5